Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

SB-271046 (SmithKline Beecham).

J J Miguel-Hidalgo¹

¹Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson 39216-4505, USA. jmiguel-hildago@psychiatry.umsmed.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|August 31, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prenatal infection decreases calbindin, decreases Purkinje cell volume and density and produces long-term motor deficits in Sprague-Dawley rats.

Developmental neuroscience·2010

Same author

Gliogenesis and glial pathology in depression.

CNS & neurological disorders drug targets·2007

Same author

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

Brain research·2002

Same author

Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder.

Biological psychiatry·2000

Same author

Immunohistochemistry of neural markers for the study of the laminar architecture in celloidin sections from the human cerebral cortex.

Journal of neuroscience methods·1999

Same author

Histone H1(o) expression in the developing cat retina.

Brain research. Developmental brain research·1999

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

SB-271046, a 5-HT6 antagonist, is being developed to enhance cognition. Studies show it increases glutamate and aspartate in the frontal cortex, suggesting potential for treating cognitive dysfunction.

Area of Science:

Neuroscience
Pharmacology

Background:

SmithKline Beecham is developing SB-271046, a selective 5-HT6 antagonist, initially for schizophrenia.
Since 1998, the primary focus shifted to treating cognitive disorders like Alzheimer's disease.

Purpose of the Study:

To evaluate SB-271046 as a potential cognition enhancer.
To investigate the neurochemical effects of SB-271046 in the brain.

Main Methods:

Phase I clinical trials commenced by December 1999.
Administration of SB-271046 and measurement of neurotransmitter levels in the frontal cortex.
Radiolabeling of SB-271046 for in vivo receptor occupancy assays.

Main Results:

SB-271046 is a potent, selective 5-HT6 antagonist (pKi = 8.9).

Related Experiment Videos

Administration significantly increased glutamate and aspartate levels in the frontal cortex.

No significant changes were observed in noradrenaline, dopamine, or 5-HT levels.

Conclusions:

SB-271046 demonstrates potential as a cognition enhancer.
The observed increase in glutamate and aspartate suggests a mechanism for treating cognitive dysfunction.
Further research may explore its therapeutic applications in neurodegenerative diseases.